- Home
- COKE vs INCY Comparison
COKE vs INCY Comparison
Compare COKE & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COKE
- INCY
- Stock Information
- Founded
- COKE 1980
- INCY 1991
- Country
- COKE United States
- INCY United States
- Employees
- COKE N/A
- INCY N/A
- Industry
- COKE Beverages (Production/Distribution)
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- COKE Consumer Staples
- INCY Health Care
- Exchange
- COKE Nasdaq
- INCY Nasdaq
- Market Cap
- COKE 12.3B
- INCY 13.4B
- IPO Year
- COKE N/A
- INCY 1993
- Fundamental
- Price
- COKE $1,382.86
- INCY $72.11
- Analyst Decision
- COKE
- INCY Buy
- Analyst Count
- COKE 0
- INCY 20
- Target Price
- COKE N/A
- INCY $74.76
- AVG Volume (30 Days)
- COKE 36.9K
- INCY 1.7M
- Earning Date
- COKE 02-20-2025
- INCY 02-10-2025
- Dividend Yield
- COKE 0.72%
- INCY N/A
- EPS Growth
- COKE 60.76
- INCY N/A
- EPS
- COKE 70.04
- INCY 0.15
- Revenue
- COKE $6,899,716,000.00
- INCY $4,241,216,999.00
- Revenue This Year
- COKE N/A
- INCY $11.81
- Revenue Next Year
- COKE N/A
- INCY $10.71
- P/E Ratio
- COKE $19.75
- INCY $427.87
- Revenue Growth
- COKE 3.69
- INCY 14.76
- 52 Week Low
- COKE $800.76
- INCY $50.35
- 52 Week High
- COKE $1,460.92
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- COKE 52.02
- INCY 51.77
- Support Level
- COKE $1,384.48
- INCY $69.75
- Resistance Level
- COKE $1,451.78
- INCY $72.69
- Average True Range (ATR)
- COKE 47.01
- INCY 2.48
- MACD
- COKE -1.95
- INCY -0.08
- Stochastic Oscillator
- COKE 41.81
- INCY 57.46
About COKE Coca-Cola Consolidated Inc.
Coca-Cola Consolidated Inc sells nonalcoholic beverage products in the United States. The company purchases concentrate and syrups from other beverage manufacturers under a license, then produces, packages, markets, and distributes the beverages to retailers. The company's primary licensor is Coca-Cola Co., which generally allows it to exclusively market, produce, and distribute Coca-Cola products in specified parts of the U.S.: North Carolina, South Carolina, West Virginia, and parts of Alabama, Georgia, Tennessee, Virginia, Indiana, and Kentucky. The company manages its business in two operating segments. Nonalcoholic Beverages segment which represents the majority of the company's revenues and All Other segments.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.